| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 103.46% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/09/2023 | 103.46% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 02/28/2023 | 93.29% | HC Wainwright & Co. | → $19 | Reiterates | → Buy |
| 11/17/2022 | 42.42% | SVB Leerink | $12 → $14 | Maintains | Outperform |
| 11/08/2022 | 93.29% | HC Wainwright & Co. | $12 → $19 | Maintains | Buy |
| 07/25/2022 | 1.73% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
| 05/23/2022 | 22.08% | SVB Leerink | → $12 | Initiates Coverage On | → Outperform |
| 03/02/2022 | 11.9% | Morgan Stanley | $10 → $11 | Maintains | Underweight |
| 02/24/2022 | 22.08% | HC Wainwright & Co. | $8 → $12 | Maintains | Buy |
| 11/05/2021 | 22.08% | JP Morgan | $7 → $12 | Upgrades | Underweight → Neutral |
| 09/16/2021 | 1.73% | Morgan Stanley | $14 → $10 | Maintains | Underweight |
| 09/16/2021 | -18.62% | HC Wainwright & Co. | $21 → $8 | Maintains | Buy |
| 09/16/2021 | 1.73% | SVB Leerink | $29 → $10 | Maintains | Outperform |
| 08/25/2021 | 42.42% | Morgan Stanley | $27 → $14 | Downgrades | Overweight → Underweight |
| 08/24/2021 | 42.42% | Cowen & Co. | $42 → $14 | Downgrades | Outperform → Market Perform |
| 08/24/2021 | 195.02% | SVB Leerink | $37 → $29 | Maintains | Outperform |
| 08/24/2021 | 83.11% | Needham | $32 → $18 | Maintains | Buy |
| 08/24/2021 | 113.63% | HC Wainwright & Co. | $32 → $21 | Maintains | Buy |
| 08/04/2021 | 276.4% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 07/16/2021 | 174.67% | Morgan Stanley | $28 → $27 | Maintains | Overweight |
| 06/28/2021 | 266.23% | SVB Leerink | $39 → $36 | Maintains | Outperform |
| 05/13/2021 | 184.84% | Morgan Stanley | $30 → $28 | Maintains | Overweight |
| 05/05/2021 | 225.53% | Needham | $40 → $32 | Maintains | Buy |
| 05/05/2021 | 296.74% | SVB Leerink | $40 → $39 | Maintains | Outperform |
| 04/01/2021 | 306.92% | SVB Leerink | $41 → $40 | Maintains | Outperform |
| 03/01/2021 | 205.19% | Morgan Stanley | $31 → $30 | Maintains | Overweight |
| 02/24/2021 | 317.09% | SVB Leerink | $35 → $41 | Maintains | Outperform |
| 12/16/2020 | 215.36% | Morgan Stanley | $32 → $31 | Maintains | Overweight |
| 11/24/2020 | 205.19% | Evercore ISI Group | → $30 | Reinstates | → Outperform |
| 11/06/2020 | 256.05% | SVB Leerink | $40 → $35 | Maintains | Outperform |
| 10/14/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 08/10/2020 | 205.19% | Piper Sandler | $35 → $30 | Maintains | Overweight |
| 08/10/2020 | 195.02% | Morgan Stanley | $30 → $29 | Maintains | Equal-Weight |
| 07/07/2020 | 195.02% | JP Morgan | → $29 | Initiates Coverage On | → Overweight |
| 06/15/2020 | 205.19% | Morgan Stanley | → $30 | Initiates Coverage On | → Equal-Weight |
| 05/13/2020 | 327.26% | Cowen & Co. | → $42 | Initiates Coverage On | → Outperform |
| 02/25/2020 | 225.53% | HC Wainwright & Co. | $30 → $32 | Maintains | Buy |
| 02/25/2020 | 256.05% | Piper Sandler | $40 → $35 | Maintains | Overweight |
| 11/06/2019 | 83.11% | Baird | $22 → $18 | Upgrades | Underperform → Neutral |
| 10/29/2019 | 154.32% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
What is the target price for Theravance Biopharma (TBPH)?
The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $20.00 expecting TBPH to rise to within 12 months (a possible 103.46% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Theravance Biopharma (TBPH)?
The latest analyst rating for Theravance Biopharma (NASDAQ: TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Theravance Biopharma (TBPH) correct?
While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $0.00 to $20.00. The current price Theravance Biopharma (TBPH) is trading at is $9.83, which is within the analyst's predicted range.